Advanced nanoscale delivery systems for mRNA-based vaccines

Biochim Biophys Acta Gen Subj. 2024 Mar;1868(3):130558. doi: 10.1016/j.bbagen.2024.130558. Epub 2024 Jan 5.

Abstract

The effectiveness of messenger RNA (mRNA) vaccines, especially those designed for COVID-19, relies heavily on sophisticated delivery systems that ensure efficient delivery of mRNA to target cells. A variety of nanoscale vaccine delivery systems (VDSs) have been explored for this purpose, including lipid nanoparticles (LNPs), liposomes, and polymeric nanoparticles made from biocompatible polymers such as poly(lactic-co-glycolic acid), as well as viral vectors and lipid-polymer hybrid complexes. Among these, LNPs are particularly notable for their efficiency in encapsulating and protecting mRNA. These nanoscale VDSs can be engineered to enhance stability and facilitate uptake by cells. The choice of delivery system depends on factors like the specific mRNA vaccine, target cell types, stability requirements, and desired immune response. In this review, we shed light on recent advances in delivery mechanisms for self-amplifying RNA (saRNA) vaccines, emphasizing groundbreaking studies on nanoscale delivery systems aimed at improving the efficacy and safety of mRNA/saRNA vaccines.

Keywords: Nanoparticles; Self-amplifying RNA (saRNA) vaccines; Vaccine delivery systems; Viral and nonviral vectors; mRNA vaccines.

Publication types

  • Review

MeSH terms

  • Polymers
  • RNA
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Vaccines*
  • mRNA Vaccines*

Substances

  • mRNA Vaccines
  • Vaccines
  • RNA
  • RNA, Messenger
  • Polymers